首页> 美国卫生研究院文献>Springer Open Choice >Managing risks in drug discovery: reproducibility of published findings
【2h】

Managing risks in drug discovery: reproducibility of published findings

机译:管理药物发现中的风险:已发表发现的可重复性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In spite of tremendous advances in biopharmaceutical science and technology, the productivity of pharmaceutical research and development has been steadily declining over the last decades. The reasons for this decline are manifold and range from improved standard of care that is more and more difficult to top to inappropriate management of technical and translational risks along the R&D value chain. In this short review, major types of risks in biopharmaceutical R&D and means to address them will be described. A special focus will be on a risk, i.e., the lack of reproducibility of published information, that has so far not been fully appreciated and systematically analyzed. Measures to improve reproducibility and trust in published information will be discussed.
机译:尽管生物制药科学和技术取得了巨大进步,但在过去的几十年中,药物研发的生产率一直在稳步下降。造成这种下降的原因是多种多样的,其范围从不断提高的护理标准到越来越难达到的最高水平,再到整个R&D价值链中对技术和转化风险的不当管理。在这篇简短的评论中,将描述生物制药研发中的主要风险类型以及解决这些风险的方法。特别要关注的是一种风险,即缺乏公开信息的可再现性,到目前为止,这种风险尚未得到充分的理解和系统地分析。将讨论提高可复制性和对已发布信息的信任的措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号